Answers are grounded in this paper and cite their sources.
Abstract A critical challenge in diffuse glioma treatment is detecting tumor infiltration during surgery to achieve safe maximal resection[1-3]. Unfortunately, safely resectable residual tumor is found in the majority of glioma patients after surgery, leading to early recurrence and decreased patient survival[4-6]. We present FastGlioma, a visual foundation model for fast (<10 seconds) and accurate detection of glioma infiltration in fresh, unprocessed surgical tissue. FastGlioma was pretrained using large-scale self-supervision (~4 million images) on rapid, label-free, optical microscopy, and fine-tuned to output a normalized score that indicates the degree of tumor infiltration within whole slide optical images. In a prospective, multicenter, international testing cohort of diffuse glioma patients (n=220), FastGlioma was able to detect and quantify the degree of tumor infiltration with an average area under the ROC curve of 92.1 ± 0.9%. FastGlioma outperformed image-guided and fluorescence-guided adjuncts for detecting tumor infiltration during surgery by a wide margin in a head-to-head, prospective comparison study (n=129). FastGlioma performance remained high across diverse patient demographics, medical centers, and diffuse glioma molecular subtypes as defined by the World Health Organization (WHO). FastGlioma shows zero-shot generalization to other adult and pediatric brain tumor diagnoses, demonstrating that our visual foundation model can serve as a general-purpose adjunct for guiding brain tumor surgeries. These findings represent the transformative potential of medical foundation models to unlock the role of artificial intelligence in the care of cancer patients.
No takes yet. Share an insight, caveat, or question.
Hollon et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: